AC Immune SA
No enriched coverage for $ACIU in the last 7 days.
No SEC Form 4 filings for $ACIU in the last 30 days.
AC Immune SA CEO Andrea Pfeifer sold 10,000 common shares in an open-market transaction on May 15, 2026, at a weighted average price of $2.7935 per share. Following this sale, Pfeifer directly holds 3,820,288 common shares, which includes 1,921,005 shares underlying restricted share units, and her spouse indirectly holds an additional 14,000 shares. This transaction was made under a 10b5-1 plan.
AC Immune SA's CEO, Andrea Pfeifer, has filed an initial statement of beneficial ownership, revealing her holdings in the company. She directly owns 3,840,288 Common Shares, which includes 1,921,005 Common Shares from restricted share units, and indirectly holds 14,000 Common Shares via her spouse. The filing also details fully vested share options with exercise prices between $2.03 and $9.53, expiring from 2027 to 2032.
AC Immune will host an industry symposium focused on a precision prevention approach to Parkinson's disease, drawing lessons from Alzheimer's. The company will also present preclinical data on its first-in-class TDP-43 PET-tracer, ACI-19626, at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2026). The symposium will cover various aspects of Parkinson's research, including alpha-synuclein targeting and interim results from the Phase 2 VacSYn trial of ACI-7104.056.
